Table 4.
Brain Regions Which Modulate Risk Based Choice
| Brain Region | Manipulation | Method | Result | Reference |
|---|---|---|---|---|
| mPFC | Bilateral Inactivation | Muscimol (GABA A) Baclofen (GABA B) |
Procedural-dependent effects | St Onge et al., 2010 |
| mPFC | D1 antagonism | SCH-23390 (D1) | ↓ Risky choice | St Onge et al., 2011 |
| mPFC | D1 agonism | SKF81297 (D1) | No effect | St Onge et al., 2011 |
| mPFC | D2 antagonism | Eticlopride (D2) | ↑ Risky choice | St Onge et al., 2011 |
| mPFC | D2 agonism | Quinpirole (D2) | ↓ Risky choice | St Onge et al., 2011 |
| ACC | Bilateral Inactivation | Muscimol (GABA A) Baclofen (GABA B) |
No effect | St Onge et al., 2010 |
| mOFC | Bilateral Inactivation | Muscimol (GABA A) Baclofen (GABA B) |
↑ Risky choice | Stopper et al., 2014 |
| OFC | Bilateral Inactivation | d-amphetamine () Flupenthixol (D1/D2) |
No effect | St Onge et al., 2010 |
| NAcc | Bilateral Inactivation | Muscimol (GABA A) Baclofen (GABA B) |
↓ Risky choice | Stopper et al., 2011 |
| NAcc | D1 agonism | SCH-23390 (D1) | ↓ Risky choice | Stopper et al., 2013 |
| NAcc | D1 agonism | SKF 81297 (D1) | ↑ Risky choice (high prob) ↓ Risky choice (low prob) |
Stopper et al., 2013 |
| NAcc | D2 antagonism | Eticlopride (D2) | No effect | Stopper et al., 2013 |
| NAcc | D2 agonism | Quinpirole (D2) Bromocriptine (D2) |
No effect | Stopper et al., 2013 |
| NAcc | D3 agonism | PD 128 907 (D3) | ↓ Risky Choice | Stopper et al., 2013 |
| NAcc Core | Bilateral Inactivation | Muscimol (GABA A) Baclofen (GABA B) |
No effect | Stopper et al., 2011 |
| NAcc Shell | Bilateral Inactivation | Muscimol (GABA A) Baclofen (GABA B) |
↓ Risky choice | Stopper et al., 2011 |
| BLA | Bilateral Inactivation | Muscimol (GABA A) Baclofen (GABA B) |
↓ Risky choice | Ghods-Sharifi et al., 2009 |